<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00717678</url>
  </required_header>
  <id_info>
    <org_study_id>PRGXLKTx-0701-TW</org_study_id>
    <nct_id>NCT00717678</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients</brief_title>
  <official_title>A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF in de Novo Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of Prograf extended
      release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The patient and graft survival rates at 6 month post-transplant</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy failure at 6-month posttransplant.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy confirmed acute rejection (Banff &gt; 1) at 6 months and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year patient and graft survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Transplantation Immunology</condition>
  <condition>Host vs Graft Reaction</condition>
  <arm_group>
    <arm_group_label>Prograf-XL + MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf + MMF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf-XL</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf-XL + MMF</arm_group_label>
    <other_name>tacrolimus extended release</other_name>
    <other_name>FK506XL</other_name>
    <other_name>MR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf + MMF</arm_group_label>
    <other_name>tacrolimus</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>oral</description>
    <arm_group_label>Prograf-XL + MMF</arm_group_label>
    <arm_group_label>Prograf + MMF</arm_group_label>
    <other_name>Mycophenolate Mofetil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been fully informed and has signed an IRB approved informed consent form
             and is willing and able to follow study procedures

          -  Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical
             living kidney transplant

          -  Patient must receive first oral dose of randomized study drug within 48 hours of
             transplant procedure

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within 7 days prior to enrollment or upon hospitalization

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than a
             kidney

          -  Patient has received a kidney transplant from a non-heart beating donor

          -  Patient has received an ABO incompatible donor kidney

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except non-metastatic basal or squamous cell carcinoma of the skin that has been
             treated successfully

          -  Patient has significant liver disease, defined as having during the past 28 days
             continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the
             upper value of the normal range of the investigational site

          -  Patient has an uncontrolled concomitant infection or any other unstable medical
             condition that could interfere with the study objectives

          -  Patient is currently taking or has been taking an investigational drug in the 30 days
             prior to transplant

          -  Patient is receiving everolimus or enteric coated mycophenolic acid at any time during
             the study

          -  Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or
             corticosteroids

          -  Patient is pregnant or lactating

          -  Patient is unlikely to comply with the visits scheduled in the protocol

          -  Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=PRGXLKTx-0701-TW</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2008</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppressant</keyword>
  <keyword>Combination drug therapy</keyword>
  <keyword>Graft loss</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Open level method</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

